SCHEMBL5035889

SCHEMBL5035889

CNC(N)=O.O=C(O)c1csc(N(C(=O)c2ccccc2Cl)c2ccc(Cl)cc2)n1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.43
POLB P06746 2/20 0.38
PTGER1 P34995 1/20 0.36
RAB9A P51151 3/20 0.36
ACHE P22303 1/20 0.36
GAA P10253 1/20 0.36
TP53 P04637 1/20 0.36
L3MBTL1 Q9Y468 3/20 0.35
ALDH1A1 P00352 2/20 0.35
SMN1; SMN2 Q16637 2/20 0.35
NPSR1 Q6W5P4 2/20 0.35
HTT P42858 1/20 0.35
PTPRB P23467 1/20 0.35
LMNA P02545 1/20 0.35
KMT2A Q03164 1/20 0.35
MAPT P10636 1/20 0.34
NPY1R P25929 1/20 0.34
NPY2R P49146 1/20 0.34
ATM Q13315 1/20 0.34
TDP1 Q9NUW8 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5034980 0.92 KDM4E (0.47) KDM4EPOLBPTGER1RAB9ATP53
SCHEMBL5036201 0.90 CYP3A4 (0.42) KDM4ERAB9AACHEGAAL3MBTL1
Methylethylamine SCHEMBL6488540 0.90 KDM4E (0.43) KDM4EPOLBPTGER1RAB9AACHE
Propylamine SCHEMBL6488547 0.88 KDM4E (0.46) KDM4EPOLBPTGER1RAB9ATP53
SCHEMBL5034975 0.86 KDM4E (0.44) KDM4EPOLBRAB9AACHETP53
SCHEMBL5032520 0.82 LMNA (0.47) KDM4EPOLBPTGER1RAB9AGAA
SCHEMBL5035887 0.81 KDM4E (0.39) KDM4ERAB9AL3MBTL1ALDH1A1SMN1; SMN2
SCHEMBL5034952 0.81 CYP3A4 (0.46) KDM4EPTGER1RAB9ASMN1; SMN2KMT2A
SCHEMBL5035149 0.81 ALDH1A1 (0.41) KDM4ERAB9AGAAALDH1A1KMT2A
SCHEMBL5032563 0.80 ALDH1A1 (0.47) KDM4EPOLBPTGER1ALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7371751-B2 Thiazole derivatives HOFFMANN-LA ROCHE INC. (US) 2008-05-13 US claimed
EP-1694673-B1 THIAZOLE DERIVATES HOFFMANN LA ROCHE (CH) 2008-01-16 EP claimed
JP-2007513193-A 2007-05-24 JP claimed
EP-1694673-A1 NOVEL THIAZOLE DERIVATES F.HOFFMANN-LA ROCHE AG (CH) 2006-08-30 EP claimed
US-20050153962-A1 Thiazole derivatives HOFFMANN-LA ROCHE INC. 2005-07-14 US claimed
WO-2005058887-A1 NOVEL THIAZOLE DERIVATES F. HOFFMANN-LA ROCHE AG (CH) 2005-06-30 WO claimed
US-7371751-B2 Thiazole derivatives HOFFMANN-LA ROCHE INC. (US) 2008-05-13 US disclosed
EP-1694673-B1 THIAZOLE DERIVATES HOFFMANN LA ROCHE (CH) 2008-01-16 EP disclosed
EP-1694673-A1 NOVEL THIAZOLE DERIVATES F.HOFFMANN-LA ROCHE AG (CH) 2006-08-30 EP disclosed
US-20050153962-A1 Thiazole derivatives HOFFMANN-LA ROCHE INC. 2005-07-14 US disclosed
WO-2005058887-A1 NOVEL THIAZOLE DERIVATES F. HOFFMANN-LA ROCHE AG (CH) 2005-06-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050153962-A1 Thiazole derivatives CNR1, CNR2, GPR119 KDM4E 3200/4885POLB 4797/4885PTGER1 237/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.